Pfizer and AstraZeneca Debate: When “the Greater Good” Matters The business pages, and now the mainstream media, have been dominated over the last week with news of Pfizer’s proposed $106bn ...

AstraZeneca (NASDAQ: AZN) and Pfizer (NYSE: PFE) -- along with one biotech stock, Exelixis (NASDAQ: EXEL). (AstraZeneca): ...

The approval comes amid speculation that AstraZeneca CEO Pascal Soriot is considering delisting its UK stock market listing for the US.

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Pfizer Inc. (NYSE:PFE) ranks among the best set-it-and-forget-it stocks to buy. On June 26, Pfizer Inc. (NYSE:PFE) declared ...

As of November 25, Pfizer's forward P/E ratio is just 8.8, considerably lower than Eli Lilly at 56.5 and AstraZeneca at 16.2. Pfizer also has a competitive price-to-book ratio of 1.54.

3SBio, which licensed Pfizer’s rights to SSGJ-707 for $1.25 billion upfront, presented mid-stage study data in a poster session that hinted at the drug’s promise in non-small cell lung cancer.

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO By Annika Kim Constantino, CNBC and Ashley Capoot, CNBC • Published June 3, 2025 ...

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO By Annika Kim Constantino, CNBC and Ashley Capoot, CNBC • Published June 3, 2025 ...

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO By Annika Kim Constantino, CNBC and Ashley Capoot, CNBC • Published June 3, 2025 ...

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO By Annika Kim Constantino, CNBC and Ashley Capoot, CNBC • Published June 3, 2025 ...